Bone Mineral Metabolism Parameters and Urinary Albumin Excretion in a Representative US Population Sample

Timothy Ellam1,2*, James Fotheringham2,3, Martin E. Wilkie2, Sheila E. Francis1, Timothy J. A. Chico1

1 Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom, 2 Sheffield Kidney Institute, Sheffield, United Kingdom, 3 School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom

Abstract

Background and Hypothesis: Even within accepted normal ranges, higher serum phosphorus, dietary phosphorus density, parathyroid hormone (PTH) and alkaline phosphatase (ALP) are independent predictors of cardiovascular mortality. Lower serum 25-hydroxy vitamin D (25(OH)D) also predicts adverse cardiovascular outcomes. We hypothesized that vascular dysfunction accompanying subtle disturbances of these bone metabolism parameters would result in associations with increased low grade albuminuria.

Study Population and Measures: We examined participants in the National Health and Nutrition Examination Surveys 1999–2010 (N = 19,383) with estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73 m² and without severe albuminuria (urine albumin:creatinine ratio (ACR) <300 mg/g). Albuminuria was quantified as ACR and fractional albumin excretion (FEalb).

Results: Increasing quintiles of dietary phosphorus density, serum phosphorus and ALP were not associated with higher ACR or FEalb. The lowest versus highest quintile of 25(OH)D was associated with greater albuminuria, but not after adjustment for other covariates including cardiovascular risk factors. An association between the highest versus lowest quintile of bone-specific ALP and greater ACR persisted after covariate adjustment, but was not accompanied by an independent association with FEalb. Increasing quintiles of PTH demonstrated associations with both higher ACR and FEalb that were not abolished by adjusting for covariates including age, gender, race, body mass index, diabetes, blood pressure, history of cardiovascular disease, smoking, eGFR, 25(OH)D, season of measurement, lipids, hemoglobin and C-reactive protein. Adjusted increases in ACR and FEalb associated with the highest versus lowest quintile of PTH were 19% (95% confidence interval 7–28% p <0.001) and 17% (8–31% p = 0.001) respectively.

Conclusion: In this population, of the bone mineral parameters associated with cardiovascular outcomes, only PTH is independently associated with ACR and FEalb.

Introduction

Even within accepted normal ranges, higher levels of serum phosphorus, dietary phosphorus density (phosphorus intake divided by energy intake), parathyroid hormone (PTH) and alkaline phosphatase (ALP), independently predict increased risk of cardiovascular events and mortality[1–10]. Lower levels of vitamin D (measured as 25-hydroxy vitamin D, 25(OH)D) also predict substantially increased cardiovascular event risk and mortality[11,12]. These observations raise the possibility that mild disturbances of the bone mineral metabolic axis contribute to cardiovascular disease and could be novel targets for disease prevention[3,11]. The mechanisms for such associations remain unclear. Advanced kidney dysfunction accompanied by major disturbances in bone mineral metabolism may promote cardiovascular disease via vascular calcification[13], but this cannot necessarily be extrapolated to more subtle differences in bone metabolic parameters. Among postulated alternative mechanisms there is some evidence linking these parameters to adverse effects on vascular endothelium[3,14–16]. Endothelium expresses receptors for both PTH and activated vitamin D, and may be sensitive to direct toxic effects of elevated phosphate[14]. Since endothelial dysfunction precedes and accompanies cardiovascular events such as myocardial infarction[17], chronic endothelial exposure to minor, yet deleterious alterations of such molecules might plausibly explain their relationship with cardiovascular risk.

Higher urinary albumin excretion rates, even at levels well below the definition of moderately increased (previously ‘micro’) albuminuria (30 mg/24 h or a urine albumin:creatinine ratio of
30 mg/g, predict cardiovascular disease events and mortality[18–
20]. The basis for this finding is uncertain, but has been attributed to
endothelial inflammation/dysfunction leading to increased
glomerular permeability[21–23]. Consequently, if bone mineral
axis dysregulation causes cardiovascular disease through adverse
effects on the endothelium, this would be predicted to increase
low-grade albuminuria. We therefore hypothesized that higher
dietary phosphorus density, serum phosphorus, PTH and ALP
and lower serum 25(OH)D are associated with increased low grade
albuminuria. We tested this hypothesis in subjects with normal
kidney function from a representative US population sample; the
US National Health and Nutrition Examination Surveys (NHANES).

Methods

Study Population

The US NHANES uses a stratified multistage sampling
procedure to create a study sample representative of the US
non-institutionalized population[24]. Certain demographic sub-
groups (non-Hispanic blacks, Mexican-Americans, and the over
60 s) are oversampled to increase the reliability of analyses in these
groups. For this analysis, data from the continuous NHANES
cycles 1999–2010 were combined. Non-pregnant participants
aged 20 y or older that attended a mobile examination center
(MEC) and were not missing data for weight, height, waist
circumference, blood pressure, serum phosphorus, calcium,
creatinine, CRP, HDL/total cholesterol, ALP, HbA1c, hemoglo-in, urine albumin:creatinine ratio (ACR), estimated dietary
phosphorus intake, diabetes status, smoking status, cardiovascular
disease history, poverty:income ratio and time of day of
venepuncture were included in the analysis. In order to determine
whether bone metabolic parameters are associated with increased
albuminuria in the general population, without confounding by
renal pathology, analyses were confined to subjects with preserved
excretory kidney function (estimated glomerular filtration rate
(eGFR) ≥60 ml/min/1.73 m²) according to the Chronic Kidney
Disease Epidemiology Collaboration eGFR equation[25]) and
normal to moderately increased albuminuria (ACR<300 mg/g).
In additional analyses, the relationships between bone metabolic
parameters and the likelihood of moderately increased albumin-
uria (ACR 30–300 mg/g) were examined.

Parathyroid hormone, 25(OH)D and bone-specific ALP mea-
surements were not performed across all NHANES cycles;
analyses involving these variables were confined to participants
from NHANES 2003–2006 (PTH and 25(OH)D) and 1999–2004
(bone-specific ALP) meeting the other criteria above.

Diabetes was defined as responding ‘Yes’ to the question ‘Have
you ever been told by a doctor or other health professional that
you have diabetes or sugar diabetes?’ or current use of insulin or
oral hypoglycemic agents. Current smoking status was classified
according to the question ‘have you used tobacco or nicotine in the
last 5 days?’ and a history of cardiovascular disease was defined by
yes to any of ‘have you ever been told you had coronary heart
disease/angina/heart attack?’ Race and ethnicity were self-
reported and for the purposes of this work were categorised as
non-Hispanic White, non-Hispanic Black, Hispanic or other.

Participant Measurements

Standing height, weight and waist circumference were mea-
sured on MEC attendance. Blood pressure was taken in a sitting
position after 5 minutes resting, using the average of the 2nd and
3rd of 3 readings. If only one measurement was obtained
successfully, this was used; if only two readings were obtained,
PTH[36], usages of these medications were incorporated into models of the association between PTH and albuminuria.

Dietary phosphorus intake analyses were adjusted additionally for estimated intake of protein; protein and phosphorus intakes are correlated, but there is some evidence that protein ingestion may affect albuminuria through glomerular hemodynamic changes independently of phosphorus[37]. The dietary phosphorus analysis was also adjusted for estimated intakes of sodium and saturated fat, which have both been associated with albuminuria in other studies[38,39].

Increasing serum phosphorus is itself associated with lower creatinine excretion rate[40], whilst greater PTH and lower 25(OH)D are associated with sarcopenia[41]. Relationships with spot urine concentrations of both albumin and creatinine were therefore reported separately, as well as their ratio. To confirm that conclusions did not simply reflect confounding by creatininuria, analyses were repeated using fractional excretion of albumin (FEalb) relative to creatinine (i.e. albumin clearance divided by creatinine clearance, calculated from paired serum and urine concentrations of both albumin and creatinine). This approach may be affected by greater proportional tubular creatinine secretion in the setting of kidney impairment, but is a physiological measure of renal albumin leak that abolishes confounding effects of muscle mass[42].

Binary logistic regression was used to determine whether bone metabolic parameters predicted a greater likelihood of participants having moderately increased albuminuria (ACR>30 mg/g).

Ethics Statement
The Research Ethics Review Board of the National Center for Health Statistics approved the NHANES data collection procedures. Written consent was obtained from participants and all data anonymized.

Results

Participant Characteristics
Of the 27,003 non-pregnant participants >20y of age in NHANES 1999–2010 with complete dietary intake and biochemistry data, 3,657 (13.5%) had eGFR<60 ml/min/1.73 m² and 310 (1.3%) with preserved GFR had severely increased albuminuria (ACR>300 mg/g). Further confining the analysis to participants with complete data for BMI, waist circumference, blood pressure, smoking status, diabetes status, history of cardiovascular disease, poverty-income ratio and time of day of venepuncture gave a total of n = 19,381 included in the analyses of serum phosphorus, total ALP and estimated dietary phosphorus intake. Similar proportions were excluded from the NHANES cycles combined for PTH, 25(OH)D and BAP analyses, leaving N = 6,005 (NHANES 2003-2006) and N = 7,384 (NHANES 1999-2004). Characteristics of the US population represented by these participants are shown in Table 1 and by quintiles of each metabolic parameter in Tables S1–S6 in File S1.

| Characteristic                           | 1999–2010 | 2003–2006 | 1999–2004 |
|-----------------------------------------|-----------|-----------|-----------|
| N                                       | 19,383    | 6,005     | 7,384     |
| Age, y, mean (SE)                       | 44.8 (0.3) | 45.2 (0.4) | 41.4 (0.3) |
| Male, % (SE)                            | 50.3 (0.3) | 50.2 (0.7) | 50.9 (0.7) |
| Race, % (SE)                            |           |           |           |
| Nonhispanic White                       | 76.8 (1.1) | 76.4 (2.2) | 77.3 (1.3) |
| Nonhispanic Black                       | 9.7 (0.6)  | 10.4 (1.3) | 9.8 (0.9)  |
| Hispanic                                | 8.0 (0.7)  | 7.9 (1.1)  | 7.8 (1.0)  |
| Other                                   | 4.9 (0.3)  | 5.0 (0.6)  | 4.5 (0.5)  |
| BMI, kg/m², mean (SE)                   | 28.3 (0.1) | 28.2 (0.2) | 27.8 (0.1) |
| Systolic BP, mm Hg, mean (SE)           | 121.4 (0.2) | 122.3 (0.4) | 120.8 (0.4) |
| Diastolic BP, mm Hg, mean (SE)          | 71.6 (0.2) | 71.3 (0.3) | 72.7 (0.2) |
| Diabetes, % (SE)                        | 6.2 (0.2)  | 6.0 (0.4)  | 4.3 (0.3)  |
| Cardiovascular disease, % (SE)          | 4.5 (0.2)  | 4.9 (0.4)  | 3.9 (0.3)  |
| Smoking, % (SE)                         | 29.8 (0.6) | 31.4 (1.1) | 32.6 (1.1) |
| eGFR, ml/min/1.73 m², mean (SE)         | 96.8 (0.3) | 96.1 (0.6) | 98.6 (0.5) |
| Serum phosphorus, mg/dl, mean (SE)      | 3.71 (0.01) | 3.83 (0.01) | 3.65 (0.01) |
| 24 h phosphorus intake, mg, mean (SE)   | 1393 (7)   | 1383 (16)  | 1387 (13)  |
| Serum calcium, mg/dl, mean (SE)         | 9.47 (0.01) | 9.54 (0.01) | 9.48 (0.02) |
| PTH, pg/ml, median (IQR)                | NA        | 38 (21)    | NA        |
| Total ALP, U/L, median (IQR)            | 66 (26)   | 64 (24)    | 67 (27)   |
| 25(OH) vitamin D, ng/mL, mean (SE)      | NA        | 24.0 (0.4) | NA        |
| BAP, ug/L, median (IQR)                 | NA        | NA        | 13.8 (6.8) |
| ACR, mg/g, median (IQR)                 | 5.8 (6.2)  | 5.9 (6.2)  | 5.6 (5.9)  |
| Urine albumin, mg/L, median (IQR)       | 6.8 (9.1)  | 6.9 (9.3)  | 6.9 (9.5)  |
| Moderate albuminuria, % (SE)            | 10.2 (0.3) | 10.1 (0.4) | 9.4 (0.5)  |

Data are given as mean (standard deviation) or median (interquartile range) for parametric and non-parametrically distributed variables respectively. N/A, not available.

Table 1. Characteristics of the US population represented by the NHANES 1999–2010, 2003–2006 and 1999–2004 cohorts.

Urine ACR, creatinine concentration, albumin concentration and FEalb were all positively skewed and were natural log-transformed for parametric analyses.

Serum Phosphorus, Dietary Phosphorus Density and Albuminuria
We first examined whether we could detect a relationship between serum phosphorus or dietary phosphorus intake and albuminuria in this large normal population. We found no increase in log-transformed ACR or FEalb, with increasing quintile of serum phosphorus concentration (Table 2). In fact, following adjustment for metabolic syndrome components (models 2/3), quintiles 2–5 were associated with a statistically significantly lower FEalb than quintile 1. Spot urine concentrations of both albumin and creatinine were significantly lower with increasing phosphorus quintile, although differences were somewhat attenuated by full covariate adjustment. Elevations of serum phosphorus within the upper quintile, although differences were somewhat attenuated by full covariate adjustment. Elevations of serum phosphorus within the normal range therefore are not associated with increased albuminuria and indeed we found some evidence that the reverse may be the case for FEalb. When these analyses were repeated in the 8,911 participants assessed after an overnight fast, there remained no association between higher-normal phosphorus and albuminuria, though the associations with lower FEalb were no longer significant (not shown).

Increasing dietary phosphorus density was also not associated with albuminuria (Table 3). In model 1, the lowest quintile of estimated dietary phosphorus density over the preceding 24 h actually had a significantly greater log ACR and FEalb than quintiles 2–3. However, full covariate adjustment (model 3) rendered these associations nonsignificant. When dietary phosphorus intake was assessed indexed to weight or as absolute unindexed intake there remained no association with greater...
### Table 2. Measures of albuminuria according to quintile of serum phosphorus.

| Serum phosphorus quintile (mg/dl) | <3.3 | 3.3–<3.6 | 3.6–<3.9 | 3.9–<4.2 | ≥4.2 |
|-----------------------------------|------|----------|----------|----------|------|
| **Model 1**                       |      |          |          |          |      |
| uAlb                             | 1    | 0.96 (0.89, 1.02) | 0.90 (0.84, 0.96) | 0.84 (0.78, 0.90) | 0.86 (0.80, 0.92) |
| uCr                              | 1    | 0.96 (0.92, 1.00) | 0.94 (0.90, 0.98) | 0.88 (0.84, 0.92) | 0.89 (0.86, 0.94) |
| ACR                              | 1    | 1.00 (0.95, 1.05) | 0.96 (0.91, 1.01) | 0.96 (0.91, 1.01) | 0.96 (0.92, 1.01) |
| FE<sub>alb</sub>                  | 1    | 0.99 (0.94, 1.04) | 0.95 (0.91, 1.00) | 0.94 (0.90, 0.99) | 0.96 (0.91, 1.01) |
| **Model 2**                       |      |          |          |          |      |
| uAlb                             | 1    | 0.97 (0.90, 1.03) | 0.92 (0.86, 0.99) | 0.85 (0.79, 0.91) | 0.87 (0.81, 0.93) |
| uCr                              | 1    | 0.97 (0.93, 1.01) | 0.95 (0.91, 0.99) | 0.90 (0.86, 0.94) | 0.91 (0.87, 0.95) |
| ACR                              | 1    | 1.00 (0.95, 1.05) | 0.97 (0.92, 1.02) | 0.95 (0.90, 1.00) | 0.96 (0.91, 1.01) |
| FE<sub>alb</sub>                  | 1    | 0.99 (0.94, 1.04) | 0.97 (0.92, 1.01) | 0.94 (0.89, 0.99) | 0.95 (0.90, 1.00) |
| **Model 3**                       |      |          |          |          |      |
| uAlb                             | 1    | 0.97 (0.92, 1.03) | 0.94 (0.89, 1.00) | 0.93 (0.87, 0.99) | 0.92 (0.87, 0.98) |
| uCr                              | 1    | 0.97 (0.93, 1.01) | 0.97 (0.93, 1.01) | 0.95 (0.92, 0.99) | 0.96 (0.93, 1.00) |
| ACR                              | 1    | 1.00 (0.96, 1.05) | 0.97 (0.93, 1.02) | 0.97 (0.93, 1.02) | 0.96 (0.91, 1.00) |
| FE<sub>alb</sub>                  | 1    | 0.93 (0.89, 0.98) | 0.94 (0.89, 0.98) | 0.93 (0.89, 0.98) | 0.93 (0.88, 0.98) |

**model 1**: adjusted for age, gender and race.

**model 2**: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes status, HbA1c.

**model 3**: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking, CRP, hemoglobin, calcium, time of day of venepuncture.

uAlb, urine albumin concentration; uCr, urine creatinine concentration; ACR, urine albumin:creatinine ratio; FE<sub>alb</sub>, fractional excretion of albumin relative to creatinine.

doi:10.1371/journal.pone.0088388.t002

### Table 3. Measures of albuminuria according to quintile of estimated dietary phosphorus density.

| Dietary phosphorus density (mg/kcal) | <0.49 | 0.49–<0.57 | 0.57–<0.66 | 0.66–<0.77 | ≥0.77 |
|-------------------------------------|------|-----------|-----------|-----------|------|
| **Model 1**                         |      |          |          |          |      |
| uAlb                               | 1    | 0.88 (0.82, 0.94) | 0.86 (0.80, 0.92) | 0.81 (0.75, 0.86) | 0.77 (0.71, 0.82) |
| uCr                                | 1    | 0.94 (0.90, 0.98) | 0.92 (0.88, 0.96) | 0.87 (0.83, 0.91) | 0.83 (0.79, 0.87) |
| ACR                                | 1    | 0.93 (0.89, 0.98) | 0.94 (0.89, 0.98) | 0.93 (0.89, 0.98) | 0.93 (0.88, 0.98) |
| FE<sub>alb</sub>                    | 1    | 0.93 (0.88, 0.98) | 0.93 (0.89, 0.98) | 0.93 (0.88, 0.97) | 0.92 (0.87, 0.97) |
| **Model 2**                         |      |          |          |          |      |
| uAlb                               | 1    | 0.90 (0.84, 0.96) | 0.88 (0.82, 0.95) | 0.84 (0.78, 0.90) | 0.81 (0.74, 0.88) |
| uCr                                | 1    | 0.94 (0.90, 0.99) | 0.92 (0.88, 0.96) | 0.86 (0.82, 0.91) | 0.82 (0.78, 0.87) |
| ACR                                | 1    | 0.95 (0.90, 1.00) | 0.96 (0.92, 1.01) | 0.97 (0.92, 1.02) | 0.98 (0.92, 1.04) |
| FE<sub>alb</sub>                    | 1    | 0.95 (0.90, 0.99) | 0.96 (0.91, 1.01) | 0.96 (0.91, 1.02) | 0.97 (0.91, 1.03) |
| **Model 3**                         |      |          |          |          |      |
| uAlb                               | 1    | 0.91 (0.85, 0.97) | 0.90 (0.84, 0.97) | 0.86 (0.80, 0.92) | 0.83 (0.76, 0.90) |
| uCr                                | 1    | 0.95 (0.91, 0.99) | 0.93 (0.89, 0.97) | 0.87 (0.83, 0.92) | 0.84 (0.79, 0.89) |
| ACR                                | 1    | 0.96 (0.91, 1.01) | 0.98 (0.93, 1.04) | 0.98 (0.93, 1.04) | 0.99 (0.93, 1.05) |
| FE<sub>alb</sub>                    | 1    | 0.96 (0.91, 1.01) | 0.98 (0.93, 1.03) | 0.98 (0.93, 1.04) | 0.99 (0.93, 1.05) |

**model 1**: adjusted for age, gender and race.

**model 2**: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes status, HbA1c and estimated 24 h calorie-indexed dietary intakes of sodium, protein and saturated fat.

**model 3**: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking, CRP, hemoglobin, calcium.

uAlb, urine albumin concentration; uCr, urine creatinine concentration; ACR, urine albumin:creatinine ratio; FE<sub>alb</sub>, fractional excretion of albumin relative to creatinine.

doi:10.1371/journal.pone.0088388.t003
albinurina (not shown). Thus we found no evidence that a greater dietary phosphorus exposure over the preceding 24 h increased albuminuria.

**Parathyroid Hormone and Albuminuria**

We next examined the relationship between PTH levels and albuminuria. NHANES participants in the top quintile of serum PTH (≥54 pg/ml) had significantly greater log ACR and FEalb compared to quintile 1 (<27 pg/ml) in model 1 (Table 4). Adjusting for covariates including metabolic syndrome components, cardiovascular risk factors, eGFR, poverty:income ratio, smoking status, CRP, hemoglobin, calcium, time of day of venepuncture, diabetes, diuretic use, season of measurement, and 25(OH)D (model 4) strengthened these associations, with statistically significant increases in ACR in the highest three quintiles of serum PTH (1.11, 1.11 and 1.19 fold respectively).

In case the excess of albuminuria in the highest quintile was influenced by primary hyperparathyroidism, we excluded subjects with PTH levels outside the reference range (i.e. above the 95th percentile of PTH, 75 pg/ml). This did not materially alter the findings; the fold-change in geometric mean ACR adjusted for all covariates was only slightly reduced to 1.16 (1.05–1.28, p = 0.003) for the 5th versus 1st PTH quintile.

### Table 4. Measures of albuminuria according to quintile of serum parathyroid hormone.

| Parathyroid Hormone Quintile (pg/ml) | <27 | 27–<34 | 34–<42 | 42–<54 | ≥54 |
|--------------------------------------|-----|--------|--------|--------|-----|
| uAlb                                | 1.09 (0.97, 1.24) | 1.16 (1.03, 1.31) | 1.28 (1.12, 1.45) | 1.34 (1.18, 1.52) |
| uCr                                 | 1.08 (0.99, 1.18) | 1.13 (1.04, 1.23) | 1.22 (1.12, 1.33) | 1.19 (1.10, 1.30) |
| ACR                                 | 1.01 (0.93, 1.10) | 1.03 (0.94, 1.12) | 1.05 (0.95, 1.15) | 1.12 (1.02, 1.23) |
| FEalb                               | 1.02 (0.93, 1.11) | 1.05 (0.94, 1.12) | 1.05 (0.96, 1.15) | 1.14 (1.04, 1.25) |

**Model 2**

- uAlb: 1.10 (0.97, 1.24) | 1.16 (1.02, 1.31) | 1.26 (1.11, 1.42) | 1.30 (1.15, 1.47) |
- uCr: 1.07 (0.99, 1.17) | 1.10 (1.01, 1.20) | 1.20 (1.10, 1.30) | 1.16 (1.06, 1.26) |
- ACR: 1.02 (0.94, 1.11) | 1.05 (0.96, 1.14) | 1.05 (0.96, 1.15) | 1.12 (1.02, 1.23) |
- FEalb: 1.02 (0.94, 1.12) | 1.04 (0.95, 1.13) | 1.04 (0.95, 1.14) | 1.13 (1.03, 1.23) |

**Model 3**

- uAlb: 1.14 (1.02, 1.29) | 1.24 (1.10, 1.40) | 1.34 (1.18, 1.52) | 1.39 (1.22, 1.57) |
- uCr: 1.08 (0.99, 1.17) | 1.12 (1.03, 1.22) | 1.21 (1.11, 1.31) | 1.17 (1.07, 1.27) |
- ACR: 1.06 (0.97, 1.16) | 1.10 (1.01, 1.20) | 1.11 (1.01, 1.21) | 1.19 (1.09, 1.30) |
- FEalb: 1.05 (0.97, 1.15) | 1.09 (1.00, 1.18) | 1.09 (0.99, 1.19) | 1.17 (1.06, 1.28) |

**Model 4**

- uAlb: 1.14 (1.01, 1.28) | 1.23 (1.09, 1.40) | 1.33 (1.17, 1.51) | 1.37 (1.20, 1.55) |
- uCr: 1.07 (0.99, 1.16) | 1.11 (1.02, 1.21) | 1.19 (1.10, 1.30) | 1.15 (1.05, 1.25) |
- ACR: 1.07 (0.98, 1.16) | 1.11 (1.02, 1.21) | 1.11 (1.01, 1.22) | 1.19 (1.08, 1.31) |
- FEalb: 1.06 (0.97, 1.15) | 1.09 (1.00, 1.19) | 1.09 (1.00, 1.20) | 1.17 (1.07, 1.28) |

model 1: adjusted for age, gender and race.
model 2: as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes status, HbA1c.
model 3: as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking status, CRP, hemoglobin, calcium, time of day of venepuncture.
model 4: as model 3 but additionally adjusted for 25(OH)D quintile, season of measurement, loop diuretic and thiazide diuretic.

**Serum 25(OH) Vitamin D and Albuminuria**

When we examined the relationship between serum vitamin D and albuminuria we found that the lowest quintile of serum 25(OH)D (<16 ng/ml) compared with the highest quintile (≥31 ng/ml) was associated with increased log-transformed ACR and FEalb in model 1 (Table 5). However, following adjustment for additional covariates (models 2–4) these associations were no longer significant.

**Alkaline Phosphatase and Albuminuria**

The top quintile of total serum ALP (≥83 U/L) was associated with significantly greater log-transformed ACR and FEalb (Table 6). This association was attenuated when adjusted for diabetes status, BMI, lipids, blood pressure and eGFR (model 2), and was abolished with adjustment for further covariates including CRP (model 3).

An association between quintile 5 versus quintile 1 of bone-specific ALP and log-transformed ACR was attenuated by full covariate adjustment (model 3) but still significant (Table 7). However, the accompanying association with FEalb did not persist.

**Odds Ratios of Microalbuminuria**

In binary logistic regression analyses, the odds ratios of moderately increased albuminuria (ACR>30 mg/g) were not
significantly different by quintile of any bone mineral metabolic parameter following covariate adjustment (not shown).

**Discussion**

Targeting the bone mineral metabolic axis for cardiovascular risk prevention is an attractive but unproven strategy. We report an independent association between higher ‘normal’ PTH and increasing low grade albuminuria, suggesting that the higher-normal range of PTH observed in the non-institutionalized US population may be associated with poorer vascular health. The magnitude of the albuminuria increase associated with PTH and cardiovascular mortality exists even at the lowest levels of ACR[19]. Although this observational analysis does not demonstrate a causative relationship, our finding is consistent with evidence linking increased PTH to endothelial/microvascular dysfunction. Such evidence comes mainly from the context of surgical correction of primary hyperparathyroidism[43–45], a state well known to be associated with increased cardiovascular mortality[46]. However, even across the normal range, higher PTH is accompanied by a substantially increased risk of cardiovascular events and mortality[5–7]. Some studies have reported associations between PTH and metabolic syndrome components[47], but in the NHANES 2001–2006 cohort, diastolic blood pressure is the only cardiovascular risk factor independently associated with greater PTH[48]. As with the reported association between PTH and cardiovascular mortality, we find that higher-normal PTH is associated with greater albuminuria independently of all traditional risk factors and previous history of cardiovascular disease.

Possible pathways to microvascular toxicity through which PTH could increase urinary albumin leak include oxidative stress induced by intracellular calcium accumulation[43], induction of a pro-inflammatory endothelial phenotype[15], or secondary elevations in aldosterone[49]. Alternatively, PTH may itself be acting as an oxidative stress marker, since oxidized PTH is inactive but not distinguished by standard PTH assays[50]. Although we excluded subjects with excretory renal impairment and adjusted for eGFR, proximal tubular dysfunction is a potential confounder that could result in both reduced albumin reabsorption and less production of PTH-suppressing calcitriol.

Targeted lowering of higher-normal PTH using calcitriol or the calcimimetic agent cinacalcet might help determine whether a healthy individual to have a PTH in the top quintile (thus what might best be targeted to lower PTH) is unclear. Investigating causal relationships between metabolic bone parameters and vascular disease is further complicated by the fact that manipulating one parameter commonly has secondary effects on the others[3].

### Table 5. Measures of albuminuria according to quintile of serum 25(OH) vitamin D.

| 25(OH) vitamin D quintile (ng/ml) | Model 1 |  16 < 26 | 22–26 | 26–31 | ≥31 |
|----------------------------------|---------|----------|--------|--------|-----|
| uAlb 1.37 (1.19, 1.57) p < 0.001 | 1.15 (1.02, 1.29) p = 0.021 | 1.20 (1.06, 1.36) p = 0.0039 | 1.08 (0.95, 1.23) p = 0.22 | 1 |
| uCr 1.18 (1.08, 1.29) p < 0.001 | 1.13 (1.04, 1.22) p = 0.0037 | 1.10 (1.01, 1.19) p = 0.029 | 1.09 (1.00, 1.19) p = 0.041 | 1 |
| ACR 1.16 (1.05, 1.28) p = 0.003 | 1.03 (0.94, 1.11) p = 0.63 | 1.09 (1.00, 1.20) p = 0.049 | 0.99 (0.91, 1.09) p = 0.86 | 1 |
| FE_{alb} 1.12 (1.01, 1.23) p = 0.028 | 1.00 (0.92, 1.09) p = 0.94 | 1.07 (0.98, 1.17) p = 0.12 | 0.98 (0.90, 1.08) p = 0.69 | 1 |

**Model 2:**

| uAlb 1.20 (1.04, 1.39) p = 0.011 | 1.07 (0.95, 1.20) p = 0.26 | 1.14 (1.01, 1.29) p = 0.038 | 1.06 (0.93, 1.20) p = 0.38 | 1 |
| uCr 1.11 (1.01, 1.21) p = 0.026 | 1.08 (0.99, 1.17) p = 0.072 | 1.05 (0.97, 1.15) p = 0.20 | 1.06 (0.98, 1.16) p = 0.14 | 1 |
| ACR 1.08 (0.98, 1.20) p = 0.11 | 0.99 (0.92, 1.08) p = 0.88 | 1.08 (0.99, 1.18) p = 0.085 | 0.99 (0.91, 1.08) p = 0.87 | 1 |
| FE_{alb} 1.03 (0.93, 1.14) p = 0.57 | 0.97 (0.89, 1.05) p = 0.42 | 1.05 (0.96, 1.14) p = 0.89 | 0.98 (0.89, 1.07) p = 0.39 | 1 |

**Model 3:**

| uAlb 1.21 (1.05, 1.39) p = 0.010 | 1.08 (0.96, 1.22) p = 0.19 | 1.15 (1.02, 1.30) p = 0.025 | 1.07 (0.94, 1.21) p = 0.31 | 1 |
| uCr 1.15 (1.05, 1.25) p = 0.032 | 1.10 (1.02, 1.19) p = 0.019 | 1.07 (0.99, 1.16) p = 0.085 | 1.08 (0.99, 1.17) p = 0.079 | 1 |
| ACR 1.05 (0.95, 1.16) p = 0.31 | 0.98 (0.91, 1.07) p = 0.71 | 1.07 (0.98, 1.17) p = 0.11 | 0.99 (0.91, 1.08) p = 0.84 | 1 |
| FE_{alb} 1.05 (0.95, 1.16) p = 0.30 | 0.99 (0.91, 1.07) p = 0.76 | 1.07 (0.98, 1.16) p = 0.13 | 0.99 (0.91, 1.08) p = 0.86 | 1 |

**Model 4:**

| uAlb 1.15 (0.99, 1.33) p = 0.067 | 1.04 (0.93, 1.17) p = 0.50 | 1.14 (1.00, 1.29) p = 0.042 | 1.05 (0.93, 1.19) p = 0.40 | 1 |
| uCr 1.13 (1.03, 1.23) p = 0.010 | 1.08 (1.00, 1.17) p = 0.053 | 1.07 (0.99, 1.16) p = 0.088 | 1.07 (0.99, 1.16) p = 0.080 | 1 |
| ACR 1.02 (0.92, 1.13) p = 0.72 | 0.96 (0.89, 1.05) p = 0.38 | 1.06 (0.97, 1.16) p = 0.19 | 0.98 (0.90, 1.07) p = 0.67 | 1 |
| FE_{alb} 1.03 (0.93, 1.14) p = 0.61 | 0.97 (0.89, 1.05) p = 0.47 | 1.06 (0.97, 1.16) p = 0.18 | 0.98 (0.90, 1.07) p = 0.72 | 1 |

**Model 1:** adjusted for age, gender and race.

**Model 2:** as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDL cholesterol ratio, eGFR, diabetes status, HbA1C.

**Model 3:** as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking status, 25(OH) vitamin D, CRP, hemoglobin, calcium and season of measurement.

**Model 4:** as model 3 but additionally adjusted for PTH quintile and time of day of venepuncture.

uAlb, urine albumin concentration; uCr, urine creatinine concentration; ACR, urine albumin:creatinine ratio; FE_{alb}, fractional excretion of albumin relative to creatinine.

doi:10.1371/journal.pone.0088388.t005
Notably, our findings linking PTH to albuminuria were independent of 25(OH)D, which was not itself associated with urinary albumin leak. This is consistent with the results of a recent study from the Korean National Health and Nutrition Examination Survey, where ascending quartile of PTH in participants >50 y was associated with increased odds of ACR>10 mg/g, but lower 25(OH)D quartile did not associate with albuminuria[54]. In contrast, a previous report from the third US NHANES cohort showed an association between lower 25(OH)D and the prevalence of moderately increased albuminuria[55]. However, that

### Table 6. Measures of albuminuria according to quintile of total alkaline phosphatase.

| Total ALP quintile (U/L) | Model 1 | 51–<61 | 61–<71 | 71–<83 | ≥83 |
|-------------------------|---------|--------|--------|--------|-----|
| uAlb                    | 1       | 1.01 (0.95, 1.08) | 1.12 (1.06, 1.19) | 1.13 (1.06, 1.21) | 1.31 (1.23, 1.39) |
| uCr                     | 1       | 1.02 (0.98, 1.06) | 1.08 (1.03, 1.12) | 1.10 (1.05, 1.14) | 1.10 (1.05, 1.14) |
| ACR                     | 1       | 1.00 (0.96, 1.04) | 1.05 (1.00, 1.09) | 1.03 (0.99, 1.08) | 1.19 (1.14, 1.25) |
| FEalb                   | 1       | 0.99 (0.95, 1.04) | 1.04 (1.00, 1.09) | 1.02 (0.98, 1.07) | 1.18 (1.13, 1.24) |
| Model 2                 | uAlb    | 1       | 0.98 (0.91, 1.05) | 1.05 (0.98, 1.12) | 1.05 (0.98, 1.13) | 1.12 (1.05, 1.20) |
| uCr                     | 1       | 1.00 (0.96, 1.05) | 1.05 (1.00, 1.10) | 1.03 (0.99, 1.08) | 1.06 (1.01, 1.11) |
| ACR                     | 1       | 0.97 (0.93, 1.02) | 1.00 (0.95, 1.05) | 0.99 (0.94, 1.04) | 1.06 (1.01, 1.11) |
| Model 3                 | uAlb    | 1       | 0.97 (0.91, 1.03) | 1.03 (0.97, 1.10) | 1.01 (0.95, 1.07) | 1.08 (1.01, 1.15) |
| uCr                     | 1       | 1.00 (0.96, 1.04) | 1.04 (1.00, 1.09) | 0.99 (0.94, 1.04) | 1.04 (1.00, 1.10) |
| ACR                     | 1       | 0.97 (0.93, 1.01) | 0.99 (0.95, 1.03) | 0.96 (0.91, 1.00) | 1.03 (0.99, 1.09) |

**model 1:** adjusted for age, gender and race.  
**model 2:** as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDLD cholesterol ratio, eGFR, diabetes status, HbA1c.  
**model 3:** as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking, CRP, alanine transaminase, aspartate transaminase, hemoglobin, calcium, phosphorus.

### Table 7. Measures of albuminuria according to quintile of bone-specific alkaline phosphatase.

| Bone-specific ALP quintile (ug/L) | Model 1 | 3.3–<3.6 | 3.6–<3.9 | 3.9–<4.2 | ≥4.2 |
|-----------------------------------|---------|-----------|----------|----------|------|
| uAlb                              | 1       | 1.18 (1.05, 1.32) | 1.15 (1.04, 1.29) | 1.22 (1.09, 1.36) | 1.46 (1.30, 1.64) |
| uCr                               | 1       | 1.11 (1.02, 1.19) | 1.11 (1.03, 1.21) | 1.14 (1.05, 1.24) | 1.14 (1.05, 1.23) |
| ACR                               | 1       | 1.07 (0.99, 1.16) | 1.03 (0.96, 1.12) | 1.07 (0.98, 1.16) | 1.29 (1.18, 1.40) |
| FEalb                             | 1       | 1.06 (0.98, 1.14) | 1.01 (0.93, 1.09) | 1.04 (0.96, 1.13) | 1.24 (1.14, 1.35) |
| Model 2                            | uAlb    | 1       | 1.14 (1.01, 1.27) | 1.08 (0.97, 1.21) | 1.12 (1.00, 1.26) | 1.28 (1.14, 1.44) |
| uCr                               | 1       | 1.09 (1.01, 1.18) | 1.09 (1.01, 1.18) | 1.13 (1.04, 1.22) | 1.14 (1.05, 1.23) |
| ACR                               | 1       | 1.04 (0.96, 1.12) | 0.99 (0.92, 1.08) | 0.99 (0.92, 1.08) | 1.13 (1.04, 1.23) |
| FEalb                             | 1       | 1.03 (0.95, 1.11) | 0.97 (0.90, 1.05) | 0.97 (0.90, 1.06) | 1.09 (1.01, 1.19) |
| Model 3                            | uAlb    | 1       | 1.12 (1.01, 1.26) | 1.07 (1.05, 1.19) | 1.09 (1.02, 1.23) | 1.24 (1.11, 1.40) |
| uCr                               | 1       | 1.09 (1.01, 1.18) | 1.09 (1.01, 1.18) | 1.12 (1.04, 1.21) | 1.14 (1.05, 1.23) |
| ACR                               | 1       | 1.03 (0.95, 1.11) | 0.97 (0.90, 1.05) | 0.98 (0.90, 1.06) | 1.10 (1.01, 1.19) |
| FEalb                             | 1       | 1.02 (0.95, 1.10) | 0.96 (0.89, 1.04) | 0.96 (0.88, 1.04) | 1.07 (0.99, 1.17) |

**model 1:** adjusted for age, gender and race.  
**model 2:** as model 1 but additionally adjusted for BMI, weight, waist circumference, systolic and diastolic blood pressures, total:HDLD cholesterol ratio, eGFR, diabetes status, HbA1c.  
**model 3:** as model 2 but additionally adjusted for history of cardiovascular disease, poverty:income ratio, smoking, CRP, hemoglobin, calcium.

doi:10.1371/journal.pone.008388.0007
analysis was not confined to participants with preserved excretory renal function and did not adjust for pre-existing cardiovascular disease or inflammatory markers. Consequently, the reported association may at least partly reflect residual confounding by lifestyle or creatininuria; subjects with cardiovascular or other comorbidity are less physically active and so have less muscle mass (thus increasing ACR independently of albumin excretion) and less sun exposure (thus lower 25(OH)D).

In contrast to a previous report from the Korean NHANES cohort[36], our study did not find any association between increasing serum phosphorus and greater albuminuria. If anything, the reverse was observed. Other than the different populations studied, the reasons for this discrepancy are not clear. Toxic effects of increasing phosphate concentrations on endothelial cells in vitro have been reported, but only at levels well above the normal range[3,14,57]. Whether endothelial dysfunction plays any role in the observed association between higher-normal serum phosphorus and cardiovascular events or kidney disease is unknown. Our findings do not provide any evidence to support a toxic vascular effect of increasing serum phosphorus across the normal range.

Shuto et al. reported an acute decline in endothelial-dependent brachial artery flow-mediated dilatation following dietary phosphorus ingestion[14], raising concerns that excessive bioavailable phosphorus in Western diets contributes to the accrual of vascular damage[3,45,58]. Dietary phosphorus intake might exert adverse vascular effects through post-prandial serum phosphorus peaks or through secondary changes in regulatory hormones such as parathyroid hormone, fibroblast growth factor-23[59] and calcitriol. A reduction in 24 h urine phosphorus, taken as a reflection of lower dietary phosphorus intake, was an independent predictor of albuminuria reduction in the PREMIER study of lifestyle interventions in obese subjects with preserved kidney function[60]. However, we did not find any association between greater estimated dietary phosphorus intake and increasing low-grade albuminuria. Dietary intake estimates were based on a single 24 h record; although a more prolonged assessment period might reveal an association between dietary phosphorus exposure and albuminuria, this time period was reported sufficient to detect an association with cardiovascular mortality[4].

Alkaline phosphatase is expressed in liver, kidneys, intestine and leukocytes as well as bone. In the NHANES 1999–2004 cohort the non-bone fraction of ALP, but not bone-specific ALP, was shown to be a mortality predictor[61], perhaps acting as a marker of inflammation and neutrophil activation. Conversely, in dialysis patients bone-specific ALP is a stronger predictor of cardiovascular mortality than total ALP, which may reflect an important link between bone-type ALP and arterial calcification[62]. We find that adjustment for covariates including CRP, metabolic syndrome factors and history of cardiovascular disease renders an association between total ALP and greater low grade albuminuria nonsignificant. Surprisingly, an association between bone-specific ALP and greater albuminuria remained significant despite full covariate adjustment. However, quantifying renal albumin permeability as FE_ab did not confirm this finding, which was thus less robust than the association between albuminuria and higher-normal PTH.

Although PTH is the only metabolic bone parameter that demonstrated a robust association with increasing low grade albuminuria, this does not mean that the ‘normal’ ranges of the other parameters are optimal for vascular health. There may be important adverse effects of subtle bone metabolic disturbances on endothelium or other vascular tissues that do not lead to increased albumin leak. Cardiovascular risk might also be mediated through other factors for which we adjusted, for example hypertension, insulin resistance and systemic inflammation[47,48,61].

Limitations

Our study has some limitations. Firstly, albuminuria assessments were performed on only a single urine sample from each participant. Since there is known to be intra-individual variation on repeat testing[63] this may have limited our ability to detect associations of modest magnitude. Similarly, dietary phosphorus intake and serum phosphorus concentration vary over time within individuals[35] so single measurements of these parameters may also limit the capture of associations. Dietary phosphorus intake estimates did not distinguish inorganic phosphates from organic phosphates, though the greater bioavailability of the former could have physiological consequences[64]. Another limitation is the lack of fibroblast growth factor-23 and calcitriol measurements; compensatory changes in these hormones occur in response to increased dietary phosphorus intake and might be important mediators of vascular dysfunction[3]. Finally, although our analyses adjusted for traditional vascular risk factors and C-reactive protein, other predictors of albuminuria have been identified for which we did not have measurement data. For example, a number of alternative inflammatory markers associated with higher urine albumin excretion independently of vascular risk factors in community populations[65].

Conclusion

Of the various metabolic bone parameters associated with cardiovascular mortality across their normal ranges, only PTH is independently and robustly associated with increasing low grade albuminuria in a representative healthy population sample. Whether interventions to re-set the metabolic bone axis improve cardiovascular outcomes remains to be determined. However, the two principle suspects for prevalent disturbance of the axis, excessive dietary phosphorus exposure and inadequate vitamin D synthesis, were not themselves associated with higher albuminuria.

Supporting Information

File S1 Tables S1–S6. Table S1. Characteristics of the US population represented by NHANES 1999–2010 participants, by quintile of serum phosphorus. Table S2. Characteristics of the US population represented by NHANES 1999–2010 participants, by quintile of dietary phosphorus density. Table S3. Characteristics of the US population represented by NHANES 2003–2006 participants, by quintile of serum parathyroid hormone. Table S4. Characteristics of the US population represented by NHANES 2003–2006 participants by quintile of serum 25-hydroxy vitamin D. Table S5. Characteristics of the US population represented by NHANES 1999–2010 participants, by quintile of serum total alkaline phosphatase. Table S6. Characteristics of the US population represented by NHANES 1999–2004 participants, by quintile of serum bone-specific alkaline phosphatase. For all supplemental tables, data are given as mean (standard deviation) or median (interquartile range) for parametric and non-parametrically distributed variables respectively. SE, standard error; IQR, interquartile range.

Acknowledgments

The authors are grateful to the NHANES participants, staff and investigators.
Author Contributions
Conceived and designed the experiments: TE. Performed the experiments: TE, JF. Analyzed the data: TE, JF, MEW, SEF. Contributed reagents/materials/analysis tools: JF. Wrote the paper: TE TJAC MEW SEF.

References
1. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D’Agostino RB Sr, et al. (2007) Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879–885.
2. Tong MJ, Sacks F, Peffer M, Gao SY, Sloman NS (2003) Relation between serum phosphorus and cardiovascular event rate in people with coronary disease. Circulation 112: 2627–2633.
3. Ellam TJ, Chico TJ (2012) Phosphat: the new cholesterol? The role of the phosphate acid in non-uremic vascular disease. Atherosclerosis 220: 310–318.
4. Chang AR, Lazo M, Appel LJ, Grijtzier OM, Grams ME. (2013) High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. Am J Clin Nutr.
5. Palmi S, Tomaszcz T, Drehcler C, Ritz E, Boehm BO, et al. Parathyroid hormone and calcium level is associated with cardiovascular mortality in patients undergoing coronary angiography. Eur Heart J 31: 1591–1598.
6. Hagstrom E, Heilmann P, Larsson TE, Ingelsson E, Bergland I, et al. (2009) Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119: 2765–2773.
7. van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA (2013) Parathyroid hormone and cardiovascular disease: A systematic review and meta-analysis of prospective studies. Am Heart J 163: 653–664, 663 e651–655.
8. Tomo N, Wang X, Selk incontro M, Stachowiak R, et al. (2009) Relation between alkaline phospatase, serum phosphat, and all-cause or cardiovascular mortality. Circulation 120: 1784–1792.
9. Abramowicz M, Munther P, Coto M, Southern W, Lewin I, et al. Serum alkaline phosphatase and phosphate level is associated with mortality and hospitalization. Clin J Am Soc Nephrol 5: 1064–1071.
10. Wannamethee SG, Sattar N, Papcosta O, Lennon L, Whincup PH (2013) Hyperparathyroidism is associated with cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 24: 1174–1180.
11. Stehouwer CD, Smulders YM (2006) Microalbuminuria and risk for cardiovascular disease. Cardiovasc Res 94: 10–19.
12. Vita JA (2011) Endothelial function. Circulation 124: e906–912.
13. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR (2011) 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular dysfunction in middle-aged and older adults. Hypertension 57: 63–69.
14. Giachelli CM (2004) Vascular calcification mechanisms. J Am Soc Nephrol 15: 2899–2904.
15. Shuto E, Taketani Y, Tanaka R, Harada N, Ishiuki M, et al. (2009) Dietary phosphorus acutely induces endothelial dysfunction. J Am Soc Nephrol 20: 1504–1512.
16. Rasahid G, Bercheim J, Green J, Benchetrit S (2007) Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 292: F1215–1218.
17. Jablonksi KL, Chonchol M, Pierce GL, Walker AE, Selk incontro M, Angielski Thomb Vase Biol 53: 1070–1076.
18. Giovannucci E, Liu Y, Hollis BW, Rimm EB (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168: 1174–1180.
19. Dohlug H, Palm S, Scharnhag H, Renner W, Schorshew U, et al. (2008) Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 168: 1340–1349.
20. Forman JP, Schenon L, de Jong PE, Bakker SJ, Cunth GC, et al. (2012) Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension. Circulation 123: 3108–3116.
21. Lin J, Judil S, Le A, Ard J, Newsome BB, et al. (2010) Associations of dietary fat, protein, and phosphorus intake is associated with all-cause mortality: results from NHANES III, 2003–2004. Am J Kidney Dis 53: 399–407.
22. Isakova T, Anderson CA, Leonard MB, Xie D, Grijtzier OM, et al. (2011) Diuretics, calcitriol and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant 26: 1250–1263.
23. Tutle KR, Brunton JI. (1992) Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 42: 167–173.
24. Visser M, Deeg JH, Lips P, Longitudinal Aging Study A (2003) Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and high parathyroid hormone levels as determinants of loss of muscle strength and mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 88: 5766–5772.
25. Ellam TJ, El Nahas M (2011) Proteinuria thresholds are irrational: a call for proteinuria indexing. Nephron Clin Pract 118: c217–c224.
26. Selvin E, Manzi J, Stevens LA, Van Lente F, Lacher DA, et al. (2007) Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988–1994, 1999–2004. Am J Kidney Dis e101053/jakd201300809.
27. Centers for Disease Control and Prevention (2010) NHANES Analytic Guidelines. Available: http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/analytical_guidelines.htm. Accessed 21 January 2013.
28. US Department of Agriculture Food Research Group. Available: http://www.ars.usda.gov/ba/fsrg. Accessed 15 May 2013.
29. Fotheringham J, Campbell MJ, Fogarty DG, El Nahas M, Ellam T (2013) Estimated Albumin Excretion Rate Versus Urine Albumin-Creatinine Ratio for the Estimation of Measured Albumin Excretion Rate: Derivation and Validation of an Estimated Albumin Excretion Rate Equation. Am J Kidney Dis doi101053/jakd201300809.
30. Park W, Kim BS, Lee JE, Huh JK, Kim BJ, et al. (2009) Serum glucose levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword. Diabetes Res Clin Pract 83: 119–125.
31. Selvin E, Manzi J, Stevens LA, Van Lente F, Lacher DA, et al. (2007) Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988–1994, 1999–2004. Am J Kidney Dis e101053/jakd201300809.
32. Centers for Disease Control and Prevention (2010) NHANES Analytic Guidelines. Available: http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/analytical_guidelines.htm. Accessed 21 January 2013.
33. US Department of Agriculture Food Research Group. Available: http://www.ars.usda.gov/ba/fsrg. Accessed 15 May 2013.
34. Fotheringham J, Campbell MJ, Fogarty DG, El Nahas M, Ellam T (2013) Estimated Albumin Excretion Rate Versus Urine Albumin-Creatinine Ratio for the Estimation of Measured Albumin Excretion Rate: Derivation and Validation of an Estimated Albumin Excretion Rate Equation. Am J Kidney Dis doi101053/jakd201300809.
35. Park W, Kim BS, Lee JE, Huh JK, Kim BJ, et al. (2009) Serum glucose levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword. Diabetes Res Clin Pract 83: 119–125.
50. Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Gron HJ, et al. (2012) Measuring parathyroid hormone (PTH) in patients with oxidative stress—do we need a fourth generation parathyroid hormone assay? PLoS One 7: e40242.

51. Talmor Y, Bernheim J, Klein O, Green J, Rashid G (2008) Calcitriol blunts pro-atherosclerotic parameters through NFκB and p38 in vitro. Eur J Clin Invest 38: 548–554.

52. Thakore P, Ho WS (2011) Vascular actions of calcimimetics: role of Ca(2+)-sensing receptors versus Ca(2+)+ influx through L-type Ca(2+)+ channels. Br J Pharmacol 162: 749–762.

53. Paik JM, Farwell WR, Taylor EN (2012) Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 23: 1727–1736.

54. Paik JM, Farwell WR, Taylor EN (2012) Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 23: 1727–1736.

55. Kim HW, Park H, Cho KH, Ko BJ (2013) Parathyroid hormone, vitamin D levels and urine albumin excretion in older persons: the 2011 Korea National Health and Nutrition Examination Survey (KNHANES). Clin Endocrinol (Oxf).

56. Paik JM, Farwell WR, Taylor EN (2012) Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 23: 1727–1736.

57. Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, et al. (2008) Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 294: F1381–1387.

58. Calvo MS, Uribarri J (2013) Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population. Am J Clin Nutr 98: 6–15.

59. Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205: 385–390.

60. Chang A, Batch BC, McGuire HL, Vollmer WM, Svetkey LP, et al. (2013) Association of a Reduction in Central Obesity and Phosphorus Intake With Changes in Urinary Albumin Excretion: The PREMIER Study. Am J Kidney Dis 62: 900–907.

61. Filipowicz R, Greene T, Wei G, Cheung AK, Raphael KL, et al. (2013) Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. Clin J Am Soc Nephrol 8: 26–32.

62. Drechsler C, Verdú M, Pile S, Krediet RT, Dekker FW, et al. (2013) Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 8: 1752–1759.

63. Selvin E, Juraschek SP, Eckfeldt J, Levey AS, Inker LA, et al. (2013) Within-person variability in kidney measures. Am J Kidney Dis 61: 716–722.

64. Karp HJ, Vathia KP, Karikkainen MU, Niemisto MJ, Lamberg-Allardt CJ (2007) Acute effects of different phosphorus sources on calcium and bone metabolism in young women: a whole-foods approach. Calcif Tissue Int 80: 251–258.

65. Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinski I, et al. (2011) Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 26: 920–926.